Anne FOGLIprofile picture None




  • 2022
  • 2021
    • E. Le Boiteux, F. Court, P. Guichet, C. Vaurs-Barriere, I. Vaillant, E. Chautard, P. Verrelle, B. Costa, L. Karayan-Tapon, A. Fogli and P. Arnaud, “Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage.”, Molecular oncology, vol. 15 (8) , pp. 1995–2010, 2021.
  • 2020
  • 2019
    • F. Court, E. Le Boiteux, A. Fogli, M. Muller-Barthelemy, C. Vaurs-Barriere, E. Chautard, B. Pereira, J. Biau, J. Kemeny, T. Khalil, L. Karayan-Tapon, P. Verrelle and P. Arnaud, “Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms.”, Genome Res., vol. 29 (10) , pp. 1605–1621, 2019.
  • 2018
    • A. Xavier-Magalhaes, C. Goncalves, A. Fogli, T. Lourenco, M. Pojo, B. Pereira, M. Rocha, M. Lopes, I. Crespo, O. Rebelo, H. Tao, J. Lima, R. Moreira, A. Pinto, C. Jones, R. Reis, J. Costello, P. Arnaud, N. Sousa and B. Costa, “The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma.”, Oncotarget, vol. 9 (21) , pp. 15740–15756, 2018.
  • 2017
    • A. Fogli, M. Demattei, L. Corset, C. Vaurs-Barriere, E. Chautard, J. Biau, J. Kemeny, C. Godfraind, B. Pereira, T. Khalil, N. Grandin, P. Arnaud, M. Charbonneau and P. Verrelle, “Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis.”, Journal of neuro-oncology, 2017.
  • 2016
    • S. Maupetit-Mehouas, B. Montibus, D. Nury, C. Tayama, M. Wassef, S. Kota, A. Fogli, F. Cerqueira Campos, K. Hata, R. Feil, R. Magueron, K. Nakabayashi, F. Court and P. Arnaud, “Imprinting control regions (ICRs) are marked by mono-allelic bivalent chromatin when transcriptionally inactive.”, Nucleic Acids Res., vol. 44 (2) , pp. 621-635, 2016.
    • A. Fogli, E. Chautard, C. Vaurs-Barriere, B. Pereira, M. Muller-Barthelemy, F. Court, J. Biau, A. Almeida Pinto, J. Kemeny, T. Khalil, L. Karayan-Tapon, P. Verrelle, B. Costa and P. Arnaud, “The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.”, Carcinogenesis, vol. 37 (2) , pp. 169-176, 2016.
  • 2014
    • F. Dutheil, G. Walther, R. Chapier, G. Mnatzaganian, B. Lesourd, G. Naughton, J. Verney, A. Fogli, V. Sapin, M. Duclos, A. Vinet, P. Obert, D. Courteix and G. Lac, “Atherogenic subfractions of lipoproteins in the treatment of metabolic syndrome by physical activity and diet - the RESOLVE trial.”, Lipids in health and disease, vol. 13 , pp. 112, 2014.
  • 2013
    • A. Lautrette, M. Fejjal, A. Aithssain, T. Phan, N. Caillot, A. Fogli and B. Souweine, “Comparison of three methods of diagnosis of plasma unmeasured anions in critically ill patients.”, Minerva Anestesiol, vol. 79 (10) , pp. 1164–72, 2013.
    • R. de Almeida, A. Fogli, M. Gaillard, G. Scheper, O. Boespflug-Tanguy and G. Pavitt, “A yeast purification system for human translation initiation factors eIF2 and eIF2Bepsilon and their use in the diagnosis of CACH/VWM disease.”, PLoS ONE, vol. 8 (1) , pp. e53958, 2013.
  • 2012
    • A. Fogli, C. Merle, V. Roussel, R. Schiffmann, S. Ughetto, M. Theisen and O. Boespflug-Tanguy, “CSF N-glycan profiles to investigate biomarkers in brain developmental disorders: application to leukodystrophies related to eIF2B mutations.”, PLoS ONE, vol. 7 (8) , pp. e42688, 2012.
    • A. Huyghe, L. Horzinski, A. Henaut, M. Gaillard, E. Bertini, R. Schiffmann, D. Rodriguez, Y. Dantal, O. Boespflug-Tanguy and A. Fogli, “Developmental splicing deregulation in leukodystrophies related to EIF2B mutations.”, PLoS ONE, vol. 7 (6) , pp. e38264, 2012.
  • 2011
    • C. Carra-Dalliere, L. Horzinski, X. Ayrignac, S. Vukusic, D. Rodriguez, F. Mauguiere, L. Peter, C. Goizet, F. Bouhour, C. Denier, C. Confavreux, M. Obadia, F. Blanc, J. de Seze, F. Sedel, A. Guennoc, E. Sartori, D. Laplaud, J. Antoine, A. Fogli, O. Boespflug-Tanguy and P. Labauge, “[Natural history of adult-onset eIF2B-related disorders: a multicentric survey of 24 cases].”, Rev. Neurol. (Paris), vol. 167 (11) , pp. 802–11, 2011.
  • 2010
    • A. Albert, M. Gaume, S. Ughetto, V. Sapin and A. Fogli, “[Coupling proteinemia and serum protein electrophoresis: evaluation of the capillary technique (Capillarys 2, Sebia), experience from Clermont-Ferrand].”, Ann. Biol. Clin. (Paris), vol. 68 (6) , pp. 657–67, 2010.
    • L. Horzinski, L. Kantor, A. Huyghe, R. Schiffmann, O. Elroy-Stein, O. Boespflug-Tanguy and A. Fogli, “Evaluation of the endoplasmic reticulum-stress response in eIF2B-mutated lymphocytes and lymphoblasts from CACH/VWM patients.”, BMC Neurol, vol. 10 , pp. 94, 2010.
    • A. Fogli and P. Bulet, “Peptidomics analysis of lymphoblastoid cell lines.”, Meth. Mol. Biol., vol. 615 , pp. 247–57, 2010.
  • 2009
    • P. Labauge, L. Horzinski, X. Ayrignac, P. Blanc, S. Vukusic, D. Rodriguez, F. Mauguiere, L. Peter, C. Goizet, F. Bouhour, C. Denier, C. Confavreux, M. Obadia, F. Blanc, J. de Seze, A. Fogli and O. Boespflug-Tanguy, “Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases.”, Brain, vol. 132 (Pt 8) , pp. 2161–9, 2009.
    • L. Horzinski, A. Huyghe, M. Cardoso, C. Gonthier, L. Ouchchane, R. Schiffmann, P. Blanc, O. Boespflug-Tanguy and A. Fogli, “Eukaryotic initiation factor 2B (eIF2B) GEF activity as a diagnostic tool for EIF2B-related disorders.”, PLoS ONE, vol. 4 (12) , pp. e8318, 2009.
  • 2008
    • A. Vanderver, Y. Hathout, J. Maletkovic, E. Gordon, M. Mintz, M. Timmons, E. Hoffman, L. Horzinski, F. Niel, A. Fogli, O. Boespflug-Tanguy and R. Schiffmann, “Sensitivity and specificity of decreased CSF asialotransferrin for eIF2B-related disorder.”, Neurology, vol. 70 (23) , pp. 2226–32, 2008.
    • O. Boespflug-Tanguy, P. Labauge, A. Fogli and C. Vaurs-Barriere, “Genes involved in leukodystrophies: a glance at glial functions.”, Curr Neurol Neurosci Rep, vol. 8 (3) , pp. 217–29, 2008.
    • A. Fogli, C. Barbier, I. Cournu-Rebeix, M. Babron, F. Clerget-Darpoux, B. Fontaine and O. Boespflug-Tanguy, “No evidence for association between the EIF2B5 gene and multiple sclerosis in French families.”, Mult. Scler., vol. 14 (4) , pp. 573, 2008.
    • L. Horzinski, C. Gonthier, D. Rodriguez, C. Scherer, O. Boespflug-Tanguy and A. Fogli, “Exon deletion in the non-catalytic domain of eIF2Bepsilon due to a splice site mutation leads to infantile forms of CACH/VWM with severe decrease of eIF2B GEF activity.”, Ann. Hum. Genet., vol. 72 (Pt 3) , pp. 410–5, 2008.
  • 2007
    • L. Roszyk, B. Faye, O. Tournilhac, A. Fogli and V. Sapin, “[Monoclonal IgM interference with immunoturbidimetric determination of ferritin and transferrin].”, Ann. Biol. Clin. (Paris), vol. 65 (6) , pp. 659–62, 2007.
    • P. Labauge, A. Fogli, F. Niel, D. Rodriguez and O. Boespflug-Tanguy, “[CACH/VWM syndrome and leucodystrophies related to EIF2B mutations].”, Rev. Neurol. (Paris), vol. 163 (8-9) , pp. 793–9, 2007.
    • S. Passemard, A. Gelot, A. Fogli, S. N'Guyen, C. Barnerias, F. Niel, D. Doummar, A. Arbues, C. Mignot, T. de Villemeur, G. Ponsot, O. Boespflug-Tanguy and D. Rodriguez, “Progressive megalencephaly due to specific EIF2Bepsilon mutations in two unrelated families.”, Neurology, vol. 69 (4) , pp. 400–2, 2007.
  • 2006
    • P. Labauge, A. Gelot, A. Fogli, O. Boespflug-Tanguy and D. Rodriguez, “Autosomal dominant leukodystrophy and childhood ataxia with central nervous system hypomyelination syndrome.”, Ann. Neurol., vol. 60 (4) , pp. 485; author reply 485–6, 2006.
    • A. Fogli, C. Malinverni, L. Thadikkaran, P. Combes, F. Perret, D. Crettaz, J. Tissot, O. Boespflug-Tanguy, R. Stocklin and P. Bulet, “Peptidomics and proteomics studies of transformed lymphocytes from patients mutated for the eukaryotic initiation factor 2B.”, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, vol. 840 (1) , pp. 20–8, 2006.
    • A. Fogli and O. Boespflug-Tanguy, “The large spectrum of eIF2B-related diseases.”, Biochemical Society transactions, vol. 34 (Pt 1) , pp. 22–9, 2006.
  • 2005
    • P. Labauge, A. Fogli, G. Castelnovo, A. Le Bayon, L. Horzinski, F. Nicoli, P. Cozzone, M. Pages, C. Briere, C. Marty-Double, O. Delhaume, A. Gelot, O. Boespflug-Tanguy and D. Rodriguez, “Dominant form of vanishing white matter-like leukoencephalopathy.”, Ann. Neurol., vol. 58 (4) , pp. 634–9, 2005.
  • 2004
    • A. Fogli, F. Gauthier-Barichard, R. Schiffmann, V. Vanderhoof, V. Bakalov, L. Nelson and O. Boespflug-Tanguy, “Screening for known mutations in EIF2B genes in a large panel of patients with premature ovarian failure.”, BMC women's health, vol. 4 (1) , pp. 8, 2004.
    • A. Fogli, R. Schiffmann, L. Hugendubler, P. Combes, E. Bertini, D. Rodriguez, S. Kimball and O. Boespflug-Tanguy, “Decreased guanine nucleotide exchange factor activity in eIF2B-mutated patients.”, European journal of human genetics : EJHG, vol. 12 (7) , pp. 561–6, 2004.
    • A. Fogli, R. Schiffmann, E. Bertini, S. Ughetto, P. Combes, E. Eymard-Pierre, C. Kaneski, M. Pineda, M. Troncoso, G. Uziel, R. Surtees, D. Pugin, M. Chaunu, D. Rodriguez and O. Boespflug-Tanguy, “The effect of genotype on the natural history of eIF2B-related leukodystrophies.”, Neurology, vol. 62 (9) , pp. 1509–17, 2004.
  • 2003
    • A. Fogli, D. Rodriguez, E. Eymard-Pierre, F. Bouhour, P. Labauge, B. Meaney, S. Zeesman, C. Kaneski, R. Schiffmann and O. Boespflug-Tanguy, “Ovarian failure related to eukaryotic initiation factor 2B mutations.”, Am. J. Hum. Genet., vol. 72 (6) , pp. 1544–50, 2003.
    • A. Fogli, D. Rodriguez, E. Eymard-Pierre and O. Boespflug-Tanguy, “[eIF2B and Cree Indian leukodystrophies].”, Med Sci (Paris), vol. 19 (3) , pp. 283–4, 2003.
    • R. Schiffmann, A. Fogli, M. van der Knaap and O. Boespflug-Tanguy, “Childhood Ataxia with Central Nervous System Hypomyelination/Vanishing White Matter”, GeneReviews, 2003.
  • 2002
    • A. Fogli, C. Dionisi-Vici, F. Deodato, A. Bartuli, O. Boespflug-Tanguy and E. Bertini, “A severe variant of childhood ataxia with central hypomyelination/vanishing white matter leukoencephalopathy related to EIF21B5 mutation.”, Neurology, vol. 59 (12) , pp. 1966–8, 2002.
    • A. Fogli, K. Wong, E. Eymard-Pierre, J. Wenger, J. Bouffard, E. Goldin, D. Black, O. Boespflug-Tanguy and R. Schiffmann, “Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus.”, Ann. Neurol., vol. 52 (4) , pp. 506–10, 2002.